{"denoms":[{"counts":[{"groupId":"BG000","value":"37"}],"units":"Participants"}],"groups":[{"description":"Participants received denosumab 120 mg once every 4 weeks (Q4W), with an additional 120 mg dose on Days 8 and 15 of the first month of treatment. All participants were instructed to take daily supplements of at least 500 mg of calcium and 400 IU of vitamin D. Participants were to continue to receive denosumab until one of the following occurred: complete tumor resection, disease progression without clinical benefit, or decision by the participant to discontinue for any reason.","id":"BG000","title":"Denosumab"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"12.3","value":"33.9"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"20"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"17"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"27"}]}],"title":"White or Caucasian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"Black or African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"Hispanic or Latino"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"Asian"}],"paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"13"}]}],"title":"Primary unresectable"},{"categories":[{"measurements":[{"groupId":"BG000","value":"18"}]}],"title":"Recurrent unresectable"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}],"title":"Recurrent resectable"}],"paramType":"NUMBER","title":"Giant Cell Tumor Disease Type","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"13"}]}],"title":"0 - Fully Active"},{"categories":[{"measurements":[{"groupId":"BG000","value":"21"}]}],"title":"1 - Restricted but ambulatory"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"2 - Ambulatory but unable to work"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"3 - Limited selfcare, confined to bed >50% daytime"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}]}],"title":"4 - Completely disabled"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"Missing"}],"description":"0: Fully active, able to carry on all pre-disease performance without restriction;\n\n1. Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work;\n2. Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours;\n3. Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours;\n4. Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair.","paramType":"NUMBER","title":"Eastern Cooperative Oncology Group (ECOG) Performance Status","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"16.1","value":"28.7"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Percent of giant cells in tumor on pre-treatment biopsy","unitOfMeasure":"percentage of giant cells in tumor"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}]}],"title":"Lower extremities"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}],"title":"Upper extremities"},{"categories":[{"measurements":[{"groupId":"BG000","value":"9"}]}],"title":"Pelvis"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"Spine"},{"categories":[{"measurements":[{"groupId":"BG000","value":"9"}]}],"title":"Pulmonary disease"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Dorsal vertebrae"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Pelvic region"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Missing"}],"paramType":"NUMBER","title":"Location of target lesion","unitOfMeasure":"participants"}]}